Agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries
DURHAM, N.C., December 07, 2021--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, "Aerie") announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countries.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Rhopressa and Rocklatan are approved and being sold in the United States by Aerie. Both Rhopressa and Rocklatan are also approved in Europe and known as Rhokiinsa and Roclanda, respectively.
"We are delighted to announce this development and commercialization agreement with Santen, a leading global ophthalmology company, which will extend the benefits of our unique products to patients with glaucoma or ocular hypertension in Europe and several other global regions. This is an expansion from our initial collaboration with Santen for Japan and East Asia, announced in October 2020, under which we have already successfully completed the first Phase 3 study for Rhopressa in Japan. Additionally, Aerie will be manufacturing these products for Santen using our new manufacturing facility in Ireland. The ability to utilize this plant for global supply will have a positive impact to reduce the manufacturing cost of our own products in the United States. We have worked hard with Santen over this past year to expand our collaboration and we look forward to Santen bringing these products to more countries," said Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman of the Board of Directors.
Story continues
Under the terms of the agreement, Aerie will receive an upfront payment of $88 million, and various development, regulatory and sales milestones of up to $77 million. Aerie is also eligible to receive additional consideration in excess of 25% of the products net sales, such consideration consisting of the cost of products supplied to Santen from Aerie and a royalty for Aeries intellectual property. Santen will be responsible for sales, marketing and pricing decisions relating to the products. Santen will also be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Roclanda. Aerie will be responsible for the manufacture and supply of the products to Santen utilizing its Athlone, Ireland plant. In addition to customary termination rights for both parties, in the event that patents are issued that may prevent the commercialization of the products in China, Santen would have the right to terminate the agreement for such country and require Aeries repayment of a portion of the upfront payment.
"With our cash and cash equivalents and investments of $168 million as of the end of the third quarter, the cash and milestones from this partnership put us in a very good financial position so that we have adequate resources to execute our business plan," said Benjamin F. McGraw, III, Pharm.D.
About Glaucoma
Glaucoma is a disorder which causes optic nerve damage leading to visual field loss and is a major cause of visual impairment including decreased vision and blindness in many countries, especially in Japan and several other Asian countries. Since glaucomatous optic nerve damage and visual field defects are generally progressive and irreversible, early detection and treatment for controlling progression of damage is crucial in the treatment of glaucoma.
About Aerie
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa, including the product label, is available at http://www.rhopressa.com. Aeries second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa and the widely-prescribed PGA (prostaglandin analog) latanoprost, was approved by the FDA and was launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan, including the product label, is available at http://www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye, wet age-related macular degeneration and diabetic macular edema. More information is available at http://www.aeriepharma.com.
Aerie Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the duration and severity of the coronavirus disease (COVID-19) outbreak, including the impact on our clinical and commercial operations, demand for our products, our financial results and condition of our global supply chains; our expectations regarding the commercialization and manufacturing of Rhopressa, Rocklatan, Rhokiinsa and Roclanda or any product candidates, preclinical implants or future product candidates, including the success of any partnerships or collaborations entered in connection therewith, including the collaboration and license agreement entered into with Santen, and the timing, cost or other aspects of their commercial launch; our commercialization, marketing, manufacturing and supply management capabilities and strategies in and outside of the United States; the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for Rhopressa and Rocklatan, with respect to regulatory approval outside of the United States, and any product candidates, preclinical implants or future product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the effectiveness of Rhopressa, Rocklatan, Rhokiinsa, Roclanda or any product candidates, preclinical implants or future product candidates; the timing of and our ability to request, obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, as applicable, Rhopressa, Rocklatan or any product candidates, preclinical implants or future product candidates; the potential advantages of Rhopressa and Rocklatan or any current or future product candidates; our plans to pursue development of additional product candidates and technologies; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma, including development of our retina program; our ability to protect our proprietary technology and enforce our intellectual property rights or to develop new intellectual property; and our expectations regarding strategic operations, including our ability to in-license or acquire additional ophthalmic products, product candidates or technologies. In particular, statements in this press release regarding our development and commercialization agreement with Santen, and payments related thereto, are forward-looking statements. In addition, FDA approval of Rhopressa and Rocklatan and EMA approval of Rhokiinsa and Roclanda do not constitute regulatory approval of Rhopressa and Rocklatan in other jurisdictions, including EMA approval of Rhokiinsa and Roclanda, and there can be no assurance that we will receive regulatory approval for Rhopressa and Rocklatan in such other jurisdictions. Additionally, FDA approval of Rhopressa and Rocklatan do not constitute FDA approval of our product candidates, preclinical implants or future product candidates and there can be no assurance that we will receive FDA approval for our product candidates, preclinical implants or future product candidates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries. Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santens website (www.santen.com).
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005829/en/
Contacts
Aerie:
Media:Carolyn McAuliffecmcauliffe@aeriepharma.com (949) 526-8733
Investors:LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.Hans Vitzthumhans@lifesciadvisors.com (617) 430-7578
Santen:
Takahiro HidakaGlobal Corporate CommunicationsSanten Pharmaceutical Co., Ltd.Email: communication@Santen.com Tel: +81-6-7664-8621
Visit link:
- Pope Francis to visit Asia and Oceania in September - Crux Now - April 16th, 2024 [April 16th, 2024]
- EY Weighs Another 100 Job Cuts in Oceania, The Australian Reports - Bloomberg - April 16th, 2024 [April 16th, 2024]
- Oceania Cruises Announces New 2025-2026 Tropics and Exotics Collection - Norwegian Cruise Line Holdings - April 16th, 2024 [April 16th, 2024]
- Pope Francis to visit 4 nations across Asia and Oceania in September - Vatican News - April 16th, 2024 [April 16th, 2024]
- Oceania Cruises Announces New 2025-26 Tropics and Exotics Collection - Cruise Industry News - April 16th, 2024 [April 16th, 2024]
- Pope Francis will head to Asia and Oceania in September for his longest foreign trip yet - America: The Jesuit Review - April 16th, 2024 [April 16th, 2024]
- Oceania Cruises Announces New Tropics and Exotics Collection for 2025-2026 - Porthole Cruise and Travel - April 16th, 2024 [April 16th, 2024]
- Per Berth Prices Rise for Oceania and Regent Newbuilds - Cruise Industry News - April 16th, 2024 [April 16th, 2024]
- Pope Francis to embark on tour of Southeast Asia, Oceania in longest papal trip - Bakersfield Now - April 16th, 2024 [April 16th, 2024]
- Pope will take his longest trip: to Asia-Oceania in September - Aleteia - April 16th, 2024 [April 16th, 2024]
- Asia/Oceania I: Korea, Republic maintain perfect record with another 3-0 win - Billie Jean King Cup - April 16th, 2024 [April 16th, 2024]
- Highlights of Billie Jean King Cup 2024 tennis tournament Asia-Oceania - Xinhua - April 16th, 2024 [April 16th, 2024]
- Oceania Cruises Announces New Tropics and Exotics Collection - Recommend Magazine - April 16th, 2024 [April 16th, 2024]
- VATICAN Pope Francis will be in Southeast Asia and Oceania from 2 to 13 September - AsiaNews - April 16th, 2024 [April 16th, 2024]
- Oceania Triathlon continental titles on the line in Taupo this weekend World Triathlon - World Triathlon - April 16th, 2024 [April 16th, 2024]
- DHL Express introduces dedicated flight between Sydney and Hong Kong to cater to Oceania-North Asia trade demand - payloadasia.com - April 16th, 2024 [April 16th, 2024]
- Vatican announces long-awaited papal visit to Asia and Oceania - Macao News - April 16th, 2024 [April 16th, 2024]
- EY confirms 148 jobs gone in mass redundancy round across Oceania - The West Australian - April 16th, 2024 [April 16th, 2024]
- Hosts Tonga launch campaign with dominant victory against American Samoa - Oceania Football Confederation - April 16th, 2024 [April 16th, 2024]
- Oceania Cruises unveils 2026 around the world voyage on Vista - TTG Asia - March 16th, 2024 [March 16th, 2024]
- Sea Control 501 Multilateral Approaches to Maritime Security in Oceania with Zach Ota | Center for International ... - CIMSEC - March 16th, 2024 [March 16th, 2024]
- Oceania set to open booking for $60K, 180-day around-the-world cruise - Business Insider - March 12th, 2024 [March 12th, 2024]
- Oceania Cruises Announces 2026 Around the World Voyage Aboard Its Newest Ship, Vista - PR Newswire - March 12th, 2024 [March 12th, 2024]
- The Oceania Vista will sail the world in 2026 - Travel Weekly - March 12th, 2024 [March 12th, 2024]
- Oceania Announces 2026 Around the World Voyage Aboard Vista - Cruise Industry News - March 12th, 2024 [March 12th, 2024]
- Oceania Championships: Record-breaking Samoan Opeloge and Australia's Elliott make moves in Olympic rankings - International Weightlifting Federation... - February 27th, 2024 [February 27th, 2024]
- Hawaii-based 'Indo-Pacific Support Cutter' focused on Oceania is on its first Pacific deployment - Honolulu Star-Advertiser - February 27th, 2024 [February 27th, 2024]
- PNG and Vanuatu to participate in inaugural FIFA Series - Football in Oceania - February 27th, 2024 [February 27th, 2024]
- OCEANIA/PAPUA NEW GUINEA - Escalation is feared after tribal conflict: The only way to avoid it is on-site dialogue - Agenzia Fides - February 27th, 2024 [February 27th, 2024]
- Brazil claim record-extending 6th FIFA Beach Soccer World Cup - Oceania Football Confederation - February 27th, 2024 [February 27th, 2024]
- NMI's Aiden Gimed wins silver in Oceania Weightlifting Championships - Marianas Variety News & Views - February 27th, 2024 [February 27th, 2024]
- Fiji U20s secures 39-25 win over Tonga at round 1 of Oceania Rugby U20s Challenge - Fijivillage - February 27th, 2024 [February 27th, 2024]
- Vakuruivalu wins bronze in the senior men's 109kg category at the Oceania Weightlifting Championship - Fijivillage - February 27th, 2024 [February 27th, 2024]
- 5G subs in SE Asia & Oceania to hit 550M by 2029-end - Nation Thailand - December 3rd, 2023 [December 3rd, 2023]
- AI image generator Stable Diffusion perpetuates racial and ... - University of Washington - December 3rd, 2023 [December 3rd, 2023]
- APCO and AIP partner to strengthen Oceania packaging industry - Packaging Gateway - December 3rd, 2023 [December 3rd, 2023]
- Solomon Islands to host OFC Women's Champions League in March - Friends of Football - December 3rd, 2023 [December 3rd, 2023]
- Tahiti tournament next prize for Wellington Olympic or Auckland City - Friends of Football - December 3rd, 2023 [December 3rd, 2023]
- Gordon Treanor joins $3bn drinks giant Suntory Oceania - The Shout - December 3rd, 2023 [December 3rd, 2023]
- LoL esports announces Japans LJL will join Oceania in PCS ... - Dexerto - December 3rd, 2023 [December 3rd, 2023]
- NZ Festival of Squash in Tauranga attracts top world and Oceania ... - Bay of Plenty Times - December 3rd, 2023 [December 3rd, 2023]
- Sisters Stephanie and Caley McNair gain international smallbore ... - Hawkes Bay Today - December 3rd, 2023 [December 3rd, 2023]
- Australian Superbike: Herfoss Earns Pole Position At "The Bend" - RoadracingWorld.com - December 3rd, 2023 [December 3rd, 2023]
- From boys' football to the Ferns in a year the rapid rise of winger ... - Friends of Football - December 3rd, 2023 [December 3rd, 2023]
- Global protein production expected to slow, but persist in 2024 - MEAT+POULTRY - December 3rd, 2023 [December 3rd, 2023]
- Catching up after the weekend? Heres all the top results and all on ... - Friends of Football - December 3rd, 2023 [December 3rd, 2023]
- All Blacks Sevens chart new beginnings in the HSBC SVNS Series - allblacks.com - December 3rd, 2023 [December 3rd, 2023]
- The Dominican Republic to host WBSC Americas U-15 Baseball ... - World Baseball Softball Confederation - December 3rd, 2023 [December 3rd, 2023]
- XXX BFA Asian Championship starts Sunday, qualifies three teams ... - World Baseball Softball Confederation - December 3rd, 2023 [December 3rd, 2023]
- Oceania - Students | Britannica Kids | Homework Help - March 31st, 2023 [March 31st, 2023]
- 5 Things You Should Know About: Oceania - WorldAtlas - March 4th, 2023 [March 4th, 2023]
- Oceania Healthcare (NZSE:OCA) Is Paying Out Less In Dividends Than Last Year - Simply Wall St - November 27th, 2022 [November 27th, 2022]
- 'Wingspan' Oceania Expansion Announced for Release Soon on iOS, Android, Switch, Xbox, and PC TouchArcade - Touch Arcade - October 30th, 2022 [October 30th, 2022]
- Oceania and Africa rising in university rankings - The PIE News - October 17th, 2022 [October 17th, 2022]
- South Asia And Oceania Pea Fiber Consumption Is Expected To Grow By Nearly 2x By 2032 - openPR - October 17th, 2022 [October 17th, 2022]
- PET Type Antiblock Masterbatch Market Size reach to 82.50 million USD in 2022-2027 With Impact of domestic and global market Top players: Review by... - October 17th, 2022 [October 17th, 2022]
- The Legend of Heroes: Trails to Azure launches on March 14, 2023 in North America; March 17 in Europe and March 24 in Oceania - RPG Site - October 17th, 2022 [October 17th, 2022]
- A 5G-proficient workforce will be in high demand: Nitin Bansal, MD, India & Head Networks, South East Asia, Oceania And India, Ericsson - The... - October 17th, 2022 [October 17th, 2022]
- Being in India more critical than ever: Ericssons Mirtillo | Mint - Mint - October 17th, 2022 [October 17th, 2022]
- Sedin lands in Melbourne with Steve de Mamiel at the helm - ARNnet - October 17th, 2022 [October 17th, 2022]
- Heavy Machinery Maintenance & Repair Demand Is Set To Reach A Valuation of US$ 284 Bn Billion 2032; Owing To Technology Integration into Service... - October 17th, 2022 [October 17th, 2022]
- WWII Ship Sunk In Oceania Shows Up In Dried-Up Californian Lake Officials Have No Idea How It Got There - IFLScience - October 15th, 2022 [October 15th, 2022]
- EY Oceania Strengthens Transformation Capability Through The Business Acquisition Of Red Moki - The Balance - October 15th, 2022 [October 15th, 2022]
- World University Rankings 2023: trends analysis - Times Higher Education - October 15th, 2022 [October 15th, 2022]
- How Africa is still paying the most for the lowest-quality internet - Benjamindada.com - October 15th, 2022 [October 15th, 2022]
- Global population hits 8 billion soon, but shrinks by 2100 - Big Think - October 15th, 2022 [October 15th, 2022]
- Banana Genomes Hint at Hidden Species We Urgently Need to Find - ScienceAlert - October 15th, 2022 [October 15th, 2022]
- Boxing: Kiwi heavyweight Hemi Ahio ready for the spotlight - New Zealand Herald - October 15th, 2022 [October 15th, 2022]
- An unbeatable moment to leverage: 2023 Womens World Cup must win hearts to change minds - The Guardian - October 15th, 2022 [October 15th, 2022]
- Architectural Services Sales Is Anticipated to Reach US$ 426.3 Bn by 2032; Rising Urbanization to Act as Key Drivers | Fact.MR's Study - GlobeNewswire - October 15th, 2022 [October 15th, 2022]
- Oceania unveils world cruise and other long voyages for 2025 - Travel Weekly - September 15th, 2022 [September 15th, 2022]
- Sailing to the Baltic Sea's top port cities with Oceania - Cruise Passenger - September 15th, 2022 [September 15th, 2022]
- Oceania Dairy tanker driver injured after truck rolls in South Cantebury - Stuff - September 15th, 2022 [September 15th, 2022]
- Study Highlights Wide Variation in Mortality of Spondyloarthritis, IBD Across the Globe - AJMC.com Managed Markets Network - September 15th, 2022 [September 15th, 2022]
- Earth had its 6th-warmest August on record - National Oceanic and Atmospheric Administration - September 15th, 2022 [September 15th, 2022]
- Humans have caused unprecedented changes to rivers - Earth.com - September 15th, 2022 [September 15th, 2022]
- From boat to bike: Georgie Howe's rapid rise to the pro ranks - CyclingTips - September 15th, 2022 [September 15th, 2022]
- Turbulence not over: Asahi pushes canned beer and healthier innovation as cost pressures heighten - FoodNavigator-Asia.com - September 15th, 2022 [September 15th, 2022]
- Auckland City keep quadruple title hopes alive with Chatham Cup football final win - Stuff - September 15th, 2022 [September 15th, 2022]
- Cruise Lines That Don't Require a COVID-19 Vaccination - Cruise Fever - September 3rd, 2022 [September 3rd, 2022]